EFFECT-FD: Effect of adding bezaFibrate to standard lipid lowering therapy on non-Fasting CholesTerol in patients with FamilialDysbetalipoproteinemia
- Conditions
- Familial Dysbetalipoproteinemia Familiaire Dysbetalipoproteinemie (dutch)
- Registration Number
- NL-OMON29530
- Lead Sponsor
- niversity Medical Center Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
1. Presence of a genetically confirmed apolipoprotein E2 homozygote
genotype or an autosomal dominant FD genotype in combination with (at
least) one of the following clinical characteristics:
Exclusion Criteria
o Use of any type of fibrate (including but not limited to gemfibrozil,
bezafibrate, fenofibrate and ciprofibrate);
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Post fatload non-HDL cholesterol.
- Secondary Outcome Measures
Name Time Method 1. Post fat load TC, HDL-C, LDL-C, TG, apoB, CRP, glucose, insulin, adipocytokines and markers of inflammation.<br /><br>2. Fasting non-HDL cholesterol.<br /><br>3. Fasting TC, HDL-C, LDL-C, TG, apoB, CRP, glucose, insulin, adipocytokines and markers of inflammation.<br /><br>4. Safety of bezafibrate.